Royal Bank of Canada
VKTX icon

Royal Bank of Canada’s Viking Therapeutics VKTX Stock Holding History

Royal Bank of Canada’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-100,000
Closed -$5.3M – 7498
2024
Q2 		$5.3M Buy
+100,000
New +$6.56M ﹤0.01% 2133
2019
Q3 		– Sell
-400
Closed -$3K – 7155
2019
Q2 		$3K Buy
+400
New +$3.42K ﹤0.01% 6501

Other funds holding VKTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Royal Bank of Canada's VKTX Position: Q1 2026 in Review

Royal Bank of Canada reduced its Viking Therapeutics (VKTX) stake by 13% in Q1 2026, selling an estimated $1.85M and leaving 397,968 shares worth $13M. The position accounts for ﹤0.01% of the portfolio, ranked #1742.

Royal Bank of Canada first reported a position in VKTX in Q4 2015 and has held it in 36 quarters since. The position peaked at $25.1M in Q3 2024. 412 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Royal Bank of Canada held 397,968 shares of Viking Therapeutics worth $13M as of Q1 2026.
  • Royal Bank of Canada sold 57,450 Viking Therapeutics shares in Q1 2026, an estimated $1.85M.
  • Viking Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #1742 holding.
  • Royal Bank of Canada first reported a position in Viking Therapeutics in Q4 2015 and has held it in 36 quarters since.
  • Royal Bank of Canada's Viking Therapeutics position peaked at $25.1M in Q3 2024.
  • 412 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.